Zealand Pharma (NASDAQ: ZEAL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.940 | -0.780 | 0.1600 | ||||
REV | 12.250M | 7.661M | -4.589M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Zealand Pharma (NASDAQ: ZEAL) through any online brokerage.
Other companies in Zealand Pharma’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Cogent Biosciences (NASDAQ:COGT), Eagle Pharmaceuticals (NASDAQ:EGRX) and Altimmune (NASDAQ:ALT).
The latest price target for Zealand Pharma (NASDAQ: ZEAL) was reported by Needham on Friday, May 13, 2022. The analyst firm set a price target for 32.00 expecting ZEAL to rise to within 12 months (a possible 144.46% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Zealand Pharma (NASDAQ: ZEAL) is $13.09 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Zealand Pharma.
Zealand Pharma’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Zealand Pharma.
Zealand Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.